Abstract
Despite their high degree of identity and even higher homology, the two Kat3 transcriptional coactivators, CBP and p300, have distinct functions, particularly within the Wnt/β-catenin signaling cascade. ICG-001, by directly binding to CBP but not p300, inhibits CBP/β-catenin transcription and has served as an invaluable chemical genomic tool to dissect the Wnt signaling cascade and the divergent roles of these two coactivators. However, to date no direct antagonist of the p300/β-catenin interaction has been reported. We now report the identification and validation of the first highly specific, direct p300/β-catenin antagonists, YH249/250 and their ability to maintain pluripotency in ESC.
Keywords: p300, CBP, Wnt signaling, peptide mimetics, stem cell, pluripotency.
Graphical Abstract
Current Molecular Pharmacology
Title:Specific Direct Small Molecule p300/β-Catenin Antagonists Maintain Stem Cell Potency
Volume: 9
Author(s): Yusuke Higuchi, Cu Nguyen, Shin-Ya Yasuda, Michael McMillan, Kouichi Hasegawa and Michael Kahn
Affiliation:
Keywords: p300, CBP, Wnt signaling, peptide mimetics, stem cell, pluripotency.
Abstract: Despite their high degree of identity and even higher homology, the two Kat3 transcriptional coactivators, CBP and p300, have distinct functions, particularly within the Wnt/β-catenin signaling cascade. ICG-001, by directly binding to CBP but not p300, inhibits CBP/β-catenin transcription and has served as an invaluable chemical genomic tool to dissect the Wnt signaling cascade and the divergent roles of these two coactivators. However, to date no direct antagonist of the p300/β-catenin interaction has been reported. We now report the identification and validation of the first highly specific, direct p300/β-catenin antagonists, YH249/250 and their ability to maintain pluripotency in ESC.
Export Options
About this article
Cite this article as:
Higuchi Yusuke, Nguyen Cu, Yasuda Shin-Ya, McMillan Michael, Hasegawa Kouichi and Kahn Michael, Specific Direct Small Molecule p300/β-Catenin Antagonists Maintain Stem Cell Potency, Current Molecular Pharmacology 2016; 9 (3) . https://dx.doi.org/10.2174/1874467208666150526155146
DOI https://dx.doi.org/10.2174/1874467208666150526155146 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
BTX AgilePulse<sup>TM</sup> System is an Effective Electroporation Device for Intramuscular and Intradermal Delivery of DNA Vaccine
Current Gene Therapy Facile Eco-compactable Design for the Synthesis and Characterization of Silver Nanoparticles
Nanoscience & Nanotechnology-Asia Pro-Inflammatory Cytokines and their Actions on the Metabolic Disturbances Associated with Cancer: Implications in Cachexia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Application of Monoclonal Antibodies as Cancer Therapy in Solid Tumors
Current Clinical Pharmacology Recent Developments of Rebeccamycin Analogues as Topoisomerase I Inhibitors and Antitumor Agents.
Current Medicinal Chemistry Exploiting EPR in Polymer Drug Conjugate Delivery for Tumor Targeting
Current Pharmaceutical Design Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials
Current Angiogenesis (Discontinued) Overview of the Role of Macrophage Migration Inhibitory Factor (MIF) in Inflammatory Bowel Disease
Current Pharmaceutical Design Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.
Current Molecular Medicine Use of Biguanides and the Risk of Colorectal Cancer: A Register-Based Cohort Study
Current Drug Safety The Characteristics, Functions and Inhibitors of Three Aminopeptidases Belonging to the M1 Family
Current Protein & Peptide Science Threes Company: Regulation of Cell Fate by Statins
Current Drug Targets - Cardiovascular & Hematological Disorders Melatonin, Autophagy and Intestinal Bowel Disease
Current Pharmaceutical Design Prebiotic Carbohydrates for Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Enhanced Free Radical Status of Cancer Cells Success and Failure of Prooxidant/Antioxidant Treatment
Current Signal Transduction Therapy Epigenetic Regulation of Genes Encoding Drug-Metabolizing Enzymes and Transporters; DNA Methylation and Other Mechanisms
Current Drug Metabolism The Targets of Curcumin
Current Drug Targets Synthesis and Biological Evaluation of Novel Heterocyclic Imines Linked Coumarin- Thiazole Hybrids as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Life and Death in the Placenta: New Peptides and Genes Regulating Human Syncytiotrophoblast and Extravillous Cytotrophoblast Lineage Formation and Renewal
Current Protein & Peptide Science Pharmacogenetic Aspects of Drug Metabolizing Enzymes in Busulfan Based Conditioning Prior to Allogenic Hematopoietic Stem Cell Transplantation in Children
Current Drug Metabolism